We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Micro-device and Nanoengineered Materials Developed To Treat Cancer and HIV

By Biotechdaily staff writers
Posted on 01 Oct 2007
Using nanotechnology, engineers have developed a small but powerful device capable of enhancing the delivery of drugs to treat life-threatening disorders.

Called an advanced drug delivery system, the innovative device has many capabilities for destroying tumors, kidney stones, and ulcers, and treating cancer and HIV. More...
Nanotechnology works with microscopic particles that are about one-millionth the size of a strand of hair. At about 16 cm3--a volume comparable to that of four kernels of popcorn--the device now in the evaluation phase, is far smaller than similar delivery systems that have been designed by other researchers.

The development effort was led by Dr. Shubhra Gangopadhyay, an electrical and computer engineering professor in the College of Engineering and head of the International Center for Nano/Micro Systems and Nanotechnology at the University of Missouri-Columbia (MO, USA). Similar to other nano/micro-scale devices developed by Dr. Gangopadhyay, this one also operates on a "dual-use” platform, which powers alternative energy and munitions systems for the U.S. military.

By integrating microchip-based technology with nanotechnology, Dr. Gangopadhyay fused both technologies to create a reaction resulting in supersonic shockwaves. For medical purposes, those shockwaves, along with nanoparticles, propagate into the body to make infected cells permeable for drug interaction. The device allows for a non-invasive procedure that utilizes the body's pores as entry points.

Other usages include the dispersion of drug-carrying nanoparticles, known as a nanosponge, into the body. Such sponges can target specific cells and areas that have been affected by disease. Other applications involve the delivery of gold nanoparticles, a florescent material, into the body. By attaching to infected cells, the unique particles can allow clinicians to track drug movement and the spread of disease throughout the body.

The researchers reported that nanoparticles contain no harmful components and are not hazardous to the body. They also stressed that the device will require as many as three more years of assessment before it is made available to pharmaceutical companies. Nems/Mems Works, LLC will market the device and various nanoparticles associated with the research.


Related Links:
University of Missouri-Columbia

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.